Table 2.
Baseline characteristics according to occurrence and type of nonfatal thrombosis during follow-up.
| No thrombosis | Arterial thrombosis | Venous thrombosis | |
|---|---|---|---|
| N = 1,348 | N = 82 | N = 84 | |
| Sex, n (%) | |||
| Female | 558 (42.0%) | 31 (37.8%) | 40 (47.6%) |
| Male | 770 (58.0%) | 51 (62.2%) | 44 (52.4%) |
| Age, years, median (IQR) | 67.0 (57.6–74.3) | 71.4 (63.2–76.3)a | 67.6 (62.8–74.0) |
| ≥65 years, n (%) | 552 (40.9%) | 46 (56.1%)a | 33 (39.3%) |
| Previous thrombosis, n (%) | 473 (35.1%) | 42 (51.2%)a | 51 (60.7%)a |
| Arterial | 362 (26.9%) | 37 (45.1%)a | 22 (26.2%) |
| Venous | 155 (11.5%) | 11 (13.4%) | 36 (42.9%)a |
| BMI, median (IQR) | 24.9 (22.9–27.4) | 25.3 (23.6–27.8) | 25.6 (23.4–29.3) |
| Normal weight, n (%) | 593 (51.1%) | 33 (44.0%) | 29 (43.3%) |
| Overweight, n (%) | 443 (38.2%) | 34 (45.3%) | 26 (38.8%) |
| Obesity, n (%) | 125 (10.8%) | 8 (10.7%) | 12 (17.9%) |
| At least one CV risk, n (%) | 844 (62.6%) | 63 (76.8%)a | 52 (61.9%) |
| Blood counts, median (IQR) | |||
| Hematocrit, % | 0.5 (0.4–0.5) | 0.5 (0.4–0.5) | 0.5 (0.4–0.5) |
| Platelets, x109/L | 353.5 (247.5–500.0) | 309.0 (229.0–482.0) | 340.5 (239.5–486.5) |
| White blood cells, x109/L | 8.9 (6.7–12.4) | 8.5 (6.2–12.0) | 8.9 (7.0–11.9) |
| eutrophils, x109/L | 6.2 (4.3–9.3) | 5.8 (3.8–9.1) | 6.8 (4.6–9.3)a |
| Lymphocytes, x109/L | 1.7 (1.3–2.3) | 1.7 (1.2–2.2) | 1.4 (1.1–1.9)a |
| Neutrophils/Lymphocytes | 3.5 (2.3–5.8) | 3.1 (2.3–5.9) | 5.1 (2.9–7.5)a |
| Treatments, n (%) | |||
| Aspirin | 456 (33.8%) | 35 (42.7%) | 29 (34.5%) |
| Phlebotomy | 870 (64.5%) | 51 (62.2%) | 57 (67.9%) |
| Hydroxyurea | 653 (48.4%) | 38 (46.3%) | 47 (56.0%) |
IQR interquartile range, BMI body mass index, CV cardiovascular.
aSignificant difference (i.e., p-value < 0.05) compared to “No thrombosis” group